Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fexlamose in moderate to severe COPD
NCT06731959Phase 2Not yet recruiting
- Sponsor
- Aer Therapeutics
- Start
- Dec 2024
- Primary completion
- Nov 2025
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Fexlamose with Placebo (2 arms). Primary endpoint: Forced Expiratory Volume in 1 Second at 4 weeks. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
fexlamose
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06731959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06731959.